ArticleBrain tumor research and treatment2018
Prognostic Evaluation of Neurological Assessment of the Neuro-Oncology Scale in Glioblastoma Patients.
Article in Brain tumor research and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Conducting a randomized controlled clinical trial on palliative care in patients with glioblastoma - what are the challenges?Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Translation and Validation of the Neurologic Assessment in Neuro-Oncology Scale into Indonesian (NANO-Ina).Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Extent of resection and perioperative neurological status as prognostic markers in glioblastoma: a population-based study.Journal of neuro-oncology · 2026Article
- Challenges of Applying the RANO-BM Criteria for Characterization of Brain Metastases Treatment Response.Current oncology (Toronto, Ont.) · 2026Review
- Expression of some circulating microRNAs as predictive biomarkers for prognosis and treatment response in glioblastoma.Scientific reports · 2025Article
- Sex-Specific Differences in Patients withAJNR. American journal of neuroradiology · 2024Article
- Treatment, healthcare utilization and outcomes in patients with glioblastoma in Ontario: a 10-year cohort study.Journal of neuro-oncology · 2024Article
- Translation and validation of the Neurological Assessment in Neuro-Oncology scale to Brazilian Portuguese.Frontiers in neurology · 2024Article
- FACTORS AFFECTING OUTCOME IN THE TREATMENT OF GLIOBLASTOMA.Acta clinica Croatica · 2022Article
- Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: a multicenter retrospective analysis.Journal of neuro-oncology · 2022Article
- Emerging role of miRNAs as liquid biopsy markers for prediction of glioblastoma multiforme prognosis.Journal of molecular neuroscience : MN · 2021Article
- The Prognostic Value of NANO Scale Assessment in IDH-Wild-Type Glioblastoma Patients.Frontiers in oncology · 2021Article
- Karnofsky Performance Scale and Neurological Assessment of Neuro-Oncology Scale as Early Predictor in Glioma.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Early imaging marker of progressing glioblastoma: a window of opportunity.Journal of neuro-oncology · 2020Article
- Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.Radiation oncology (London, England) · 2019Article
- An Inflammatory Landscape for Preoperative Neurologic Deficits in Glioblastoma.Frontiers in genetics · 2019Article
- Predictive value of brain tumor reporting and data system scores for functional outcomes and progression-free survival in glioblastoma.Neuro-oncology advancesArticle
- Rethinking treatment de-escalation in elderly glioblastoma: Lessons from a multicenter real-world cohort.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aims of this study were to investigate the role of the Neurological Assessment of Neuro-Oncology (NANO) scale in predicting the prognosis of patients with glioblastoma, and compare these results to predicted data of the Karnofsky Performance Scale (KPS), and Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status. Additionally, we examined other prognostic factors in glioblastoma patients.
methodsThe medical records of 76 patients with a new diagnosis of histologically ascertained glioblastoma in the period from January 2002 to December 2015 at the authors' institution were retrospectively reviewed. Clinical factors, including epidemiologic, radiologic, and therapeutic values were reviewed as well as the performance status assessed by the KPS, ECOG/WHO performance status, and NANO scale.
resultsThe mean overall survival was 19.8 months (95% confidence interval 15.2-25.4 months). At initial diagnosis, the mean value [±standard deviation (SD)] of KPS score, ECOG/WHO performance status, and NANO scale were 81 (±7.4), 1.3 (±0.6), and 7.3 (±3.8), respectively. Multivariate analysis for predicting survival showed odds ratios of KPS score, ECOG/WHO performance status, and NANO scale were 2.502 (≥80 vs. <80; p=0.024), 1.691 (0-1 vs. 2-5; p=0.047), and 2.763 (0-7 vs. 8-23; p=0.020), respectively. At the time of progression, the mean value (±SD) of KPS score, ECOG/WHO performance status, and NANO scale were 69 (±8.2), 1.6 (±0.7), and 11.4 (±4.2), respectively; multivariate analysis for predicting survival showed that the odd ratios for KPS score, ECOG/WHO performance status, and NANO scale were 2.007 (≥80 vs. <80; p=0.035), 1.321 (0-1 vs. 2-5; p=0.143), and 3.182 (0-7 vs. 8-23; p=0.002), respectively.
conclusionThe NANO scale provided a more detailed and objective measure of neurologic function than that currently used for predicting the prognosis of glioblastoma patients, especially at the time of progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.